{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:33Z","timestamp":1790931333835,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08031-w","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:52:56Z","timestamp":1782906776000},"page":"6881-6896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET\/CT, alongside identification of suitable candidates for targeted radionuclide therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Shyam Kumar","family":"Ravada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Vithalrao","family":"Parghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouri","family":"Pantvaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"8031_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567\u2013610.","journal-title":"Thyroid"},{"key":"8031_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.864253","volume":"13","author":"A Matrone","year":"2022","unstructured":"Matrone A, Gambale C, Prete A, Elisei R. Sporadic medullary thyroid carcinoma: towards a precision medicine. Front Endocrinol (Lausanne). 2022;13:864253.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8031_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.6004\/jnccn.2010.0042","volume":"8","author":"JF Moley","year":"2010","unstructured":"Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8:549\u201356.","journal-title":"J Natl Compr Canc Netw"},{"key":"8031_CR4","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.3390\/cancers13184670","volume":"13","author":"H Park","year":"2021","unstructured":"Park H, Yang H, Heo J, Kim TH, Kim SW, Chung JH. Long-term outcomes and causes of death among medullary thyroid carcinoma patients with distant metastases. Cancers (Basel). 2021;13:4670.","journal-title":"Cancers (Basel)"},{"key":"8031_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1754-9485.2012.02344.x","volume":"56","author":"X Cheng","year":"2012","unstructured":"Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y. 18F-FDG-PET and 18F-FDG PET\/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2012;56:136\u201342.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"8031_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14310\/horm.2002.1756","volume":"16","author":"G Treglia","year":"2017","unstructured":"Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16:362\u201372.","journal-title":"Hormones (Athens)"},{"key":"8031_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","volume":"47","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8031_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med"},{"key":"8031_CR9","doi-asserted-by":"crossref","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u2013354.","DOI":"10.1007\/s00259-014-2961-x"},{"key":"8031_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.124.269002","volume":"66","author":"TA Hope","year":"2025","unstructured":"Hope TA, Calais J, Goenka AH, et al. SNMMI Procedure Standard\/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2025;66:26\u201333.","journal-title":"J Nucl Med"},{"issue":"8","key":"8031_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716\u201331.","journal-title":"Eur J Nucl Med"},{"key":"8031_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, et al. Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128:549\u201355.","journal-title":"Br J Cancer"},{"key":"8031_CR13","unstructured":"[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. NCCN.org. Available athttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf -Version 1.2025 \u2014 March 27, 2025"},{"key":"8031_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3803\/EnM.2021.1082","volume":"36","author":"M Kim","year":"2021","unstructured":"Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2021;36:514\u201324.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"8031_CR15","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.12.10370","author":"D Ganeshan","year":"2013","unstructured":"Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol. 2013. https:\/\/doi.org\/10.2214\/ajr.12.10370.","journal-title":"AJR Am J Roentgenol"},{"key":"8031_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1381863","volume":"11","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Albano D, Dondi F, et al. Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review. Front Med (Lausanne). 2024;11:1381863.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"8031_CR17","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","volume":"53","author":"HH Verbeek","year":"2012","unstructured":"Verbeek HH, Plukker JT, Koopmans KP, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53(12):1863\u201371.","journal-title":"J Nucl Med"},{"key":"8031_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","volume":"15","author":"Z Kong","year":"2025","unstructured":"Kong Z, Li Z, Cui XY, et al. CTR-FAPI PET enables precision management of medullary thyroid carcinoma. Cancer Discov. 2025;15:316\u201328.","journal-title":"Cancer Discov"},{"key":"8031_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/RLU.0000000000005558","volume":"50","author":"EG Isik","year":"2025","unstructured":"Isik EG, Has Simsek D, Gul N, et al. Head-to-head comparison of 68Ga-FAPI-04 and 68Ga-DOTA-TATE PET\/CT in recurrent medullary thyroid cancer. Clin Nucl Med. 2025;50:80\u20136.","journal-title":"Clin Nucl Med"},{"key":"8031_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/thy.2023.0008","volume":"33","author":"S Ballal","year":"2023","unstructured":"Ballal S, Yadav MP, Roesch F, et al. Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC positron emission tomography\/computed tomography imaging for the follow-up surveillance of patients with medullary thyroid cancer. Thyroid. 2023;33:974\u201382.","journal-title":"Thyroid"},{"key":"8031_CR21","doi-asserted-by":"publisher","unstructured":"Basu S, Ravada SK, Parghane RV, Adnan A, Padwal M, Basu B. Inter- and intra-quartile comparison of multi-tracer PET\/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a \u201cstepped care\u201d model for individualized precision theranostics through AI\/ML. Eur J Nucl Med Mol Imaging. 2026. https:\/\/doi.org\/10.1007\/s00259-026-08025-8","DOI":"10.1007\/s00259-026-08025-8"},{"issue":"8","key":"8031_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2967\/jnumed.125.269914","volume":"66","author":"E Novruzov","year":"2025","unstructured":"Novruzov E, Sheikh GT, Mamlins E, et al. Meeting upcoming clinical and diagnostic needs in oncologic imaging: a structured reporting system for fibroblast-activation-protein-targeted imaging-FAP-RADS version 1.0. J Nucl Med. 2025;66(8):1245\u201351.","journal-title":"J Nucl Med"},{"key":"8031_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040839","volume":"16","author":"P Guglielmo","year":"2024","unstructured":"Guglielmo P, Alongi P, Baratto L, et al. FAPi-based agents in thyroid cancer: a new step towards diagnosis and therapy? A systematic review of the literature. Cancers (Basel). 2024;16:839.","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08031-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08031-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08031-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:02Z","timestamp":1790929922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08031-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8031"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08031-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patients participating in the study.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yes, approved by the Institutional Medical Ethics Committee (IEC).","order":3,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}}]}}